Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

InControl Medical LLC

Electronic nerve stimulation for female urinary incontinence

This article was originally published in Start Up

Executive Summary

Transcutaneous electrical nerve stimulation technology has been used for decades to noninvasively treat acute and chronic pain in the muscles, joints, back, and neck. Now, InControl Medical LLC is employing it in the form of an intravaginal probe combined with patient biofeedback and quantitative physician feedback to treat one of the largest and fastest growing female health care problems, stress and mixed urinary incontinence.

You may also be interested in...



Medtech Solutions For The "Other" Incontinence

Fecal incontinence is a common, devastating condition that often goes untreated. Eyeing the potential multibillion-dollar opportunity, medtech start-ups are developing approaches that range from small and disposable to surgical and permanent.

Medtech Start-Ups Innovate In Urinary Incontinence

Angel- and venture-backed medtech start-ups are working to fill the tremendous unmet need for alternative device options for treating (not just managing) female urinary incontinence a condition that has a significant impact on quality of life for millions of women. In this issue we profile Floelle, InControl Medical, NexHand, and Solace Therapeutics.

Podcast: NodThera On The Role Of The Brain In Driving Chronic Disease

Alan Watt, CEO of NodThera, a clinical-stage biotech developing brain-penetrant NLRP3 inflammasome inhibitors to treat chronic inflammatory diseases, talks to In Vivo about the company’s pipeline and recent data publication in the field of obesity. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037768

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel